Our top pick for
Oncolytics Biotech Inc is a biotechnology business based in the US. Oncolytics Biotech shares (ONCY) are listed on the NASDAQ and all prices are listed in US Dollars. Oncolytics Biotech employs 25 staff and has a market cap (total outstanding shares value) of 0.00.
|52-week range||$0.94 - $4.19|
|50-day moving average||$2.93|
|200-day moving average||$2.41|
|Wall St. target price||N/A|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.83|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||$0|
|Return on assets TTM||-58.93%|
|Return on equity TTM||-182.63%|
|Market capitalisation||$145.6 million|
TTM: trailing 12 months
There are currently 891,018 Oncolytics Biotech shares held short by investors – that's known as Oncolytics Biotech's "short interest". This figure is 7.5% up from 828,747 last month.
There are a few different ways that this level of interest in shorting Oncolytics Biotech shares can be evaluated.
Oncolytics Biotech's "short interest ratio" (SIR) is the quantity of Oncolytics Biotech shares currently shorted divided by the average quantity of Oncolytics Biotech shares traded daily (recently around 1.4 million). Oncolytics Biotech's SIR currently stands at 0.65. In other words for every 100,000 Oncolytics Biotech shares traded daily on the market, roughly 650 shares are currently held short.
However Oncolytics Biotech's short interest can also be evaluated against the total number of Oncolytics Biotech shares, or, against the total number of tradable Oncolytics Biotech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Oncolytics Biotech's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Oncolytics Biotech shares in existence, roughly 20 shares are currently held short) or 0.0194% of the tradable shares (for every 100,000 tradable Oncolytics Biotech shares, roughly 19 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Oncolytics Biotech.
Find out more about how you can short Oncolytics Biotech stock.
We're not expecting Oncolytics Biotech to pay a dividend over the next 12 months.
Oncolytics Biotech's shares were split on a 10:95 basis on 24 May 2018. So if you had owned 95 shares the day before before the split, the next day you'd have owned 10 shares. This wouldn't directly have changed the overall worth of your Oncolytics Biotech shares – just the quantity. However, indirectly, the new 850% higher share price could have impacted the market appetite for Oncolytics Biotech shares which in turn could have impacted Oncolytics Biotech's share price.
Over the last 12 months, Oncolytics Biotech's shares have ranged in value from as little as $0.94 up to $4.19. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Oncolytics Biotech's is 1.9314. This would suggest that Oncolytics Biotech's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Oncolytics Biotech Inc. , a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an immuno-oncology viral-agent for the treatment of solid tumors and hematological malignancies. The company has collaboration agreements with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone-receptor positive, human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.
Everything we know about the TC Bancshares IPO, plus information on how to buy in.
Everything we know about the Soulgate IPO, plus information on how to buy in.
Everything we know about the Alzamend Neuro IPO, plus information on how to buy in.
Everything we know about the Singular Genomics Systems IPO, plus information on how to buy in.
Everything we know about the Golden Sun Education Group Limited IPO, plus information on how to buy in.
Everything we know about the Phillips Edison & Company IPO, plus information on how to buy in.
Everything we know about the FIGS IPO, plus information on how to buy in.
Everything we know about the DLocal Limited IPO, plus information on how to buy in.
Everything we know about the Torchy’s Tacos IPO, plus information on how to buy in.
Everything we know about the Dutch Bros Coffee IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.